Eric Mark Green
Insider (Form 4 reporting owner): Director CIK 1336007Name as filed: Green Eric MarkIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 5 Dec 2022, sold $114.7M in 7 sales (3 under a 10b5-1 plan set in advance) and bought $1.0M in 1 open-market purchase across 2 companies.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| West Pharmaceutical Services WST | President, CEO and Board Chair | 5 Dec 2022 | 6 Aug 2024 | – | 7$114.7M |
| Ecolab ECL | Director | 11 Sep 2026 | 11 Sep 2026 | 1$1.0M | – |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After purchases | no trade old enough | no trade old enough | no trade old enough |
| After sales | +8.1 pts7 trades, 57% above the sector | -2.2 pts7 trades, 43% above the sector | -9.0 pts7 trades, 14% above the sector |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | 1 | $1.0M | – | – | $1.0M |
| 2024 | – | – | 3 | $56.6M | -$56.6M |
| 2023 | – | – | 3 | $47.5M | -$47.5M |
| 2022 | – | – | 1 | $10.5M | -$10.5M |
Every trade
9, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 11 Sep 2026 | Ecolab ECL | Buy | 3,690 | $276.64 | $1.0M | No | Form 4filed 14 Sep 2026 |
| 6 Aug 2024 | West Pharmaceutical Services WST | Sellafter exercising options | 30,732 | $304.71 | $9.4M | 10b5-1 plan | Form 4filed 8 Aug 2024 |
| 7 May 2024 | West Pharmaceutical Services WST | Sellamended filing (4/A), not counted again; after exercising options | 66,000 | $366.65 | $24.2M | 10b5-1 plan | Form 4/Afiled 8 Aug 2024 |
| 7 May 2024 | West Pharmaceutical Services WST | Sellafter exercising options | 66,000 | $366.65 | $24.2M | No | Form 4filed 9 May 2024 |
| 27 Feb 2024 | West Pharmaceutical Services WST | Sellafter exercising options | 64,132 | $359.85 | $23.1M | 10b5-1 plan | Form 4filed 29 Feb 2024 |
| 8 Aug 2023 | West Pharmaceutical Services WST | Sellafter exercising options | 44,000 | $394.77 | $17.4M | 10b5-1 plan | Form 4filed 10 Aug 2023 |
| 9 May 2023 | West Pharmaceutical Services WST | Sellafter exercising options | 44,000 | $363.11 | $16.0M | No | Form 4filed 11 May 2023 |
| 7 Mar 2023 | West Pharmaceutical Services WST | Sellafter exercising options | 44,000 | $322.35 | $14.2M | Not stated | Form 4filed 9 Mar 2023 |
| 5 Dec 2022 | West Pharmaceutical Services WST | Sellafter exercising options | 44,000 | $238.99 | $10.5M | Not stated | Form 4filed 8 Dec 2022 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.